JAK2^V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia

Abstract

The results indicate that JAK2(V617F) mutation is associated with clinical and morphological features of the myeloproliferative type of CMML. Therefore, JAK2 mutation analysis together with bone marrow morphology could help in a more appropriate classification of the disease.